Warning: Undefined variable $subreddit_drop in /home3/thegood9/public_html/website_70aad9ea/functions.php on line 998

Warning: Undefined array key "thumbnail" in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 25
StackHealth / FDA commissioner Marty Makary resigns amid mounting scrutiny

F.D.A. Commissioner Marty Makary Resigns After Weeks of Pressure

Christina Jewett / nytimes - The agency’s top food official will step in as acting commissioner, after Dr. Makary’s tumultuous run as the nation’s top food, drug, tobacco and medical device regulator.

AI Summary: F.D.A. commissioner Marty Makary resigned after weeks of intense scrutiny and internal pressure over leadership and policy choices, following reports he faced possible removal. The agency now confronts leadership turbulence as officials rush to steady regulatory priorities, reassure stakeholders and clean up an exit that leaves unfinished reviews and awkward staff memos.

#healthcare #pharmaceuticals #publichealth #governmentpolicy #drugdevelopment #fda

Firing reports and buildup to Makary's ouster


Regulatory ripple effects and agency departures


Resignation announced and immediate leadership vacuum


All Other Stories

13 days / medicalxpress

13 days / medicalxpress

14 days / oncodaily

15 days / medicalxpress


Back to Top / Tuesday, May 12, 2026, 1:23 pm / permalink 23656 / 18 stories in 19 days /


Blog Post
FDA Commissioner Marty Makary has resigned after weeks of intense scrutiny and internal pressure, multiple outlets reported. The resignation follows reports that President Trump had approved a plan to oust Makary — a report the White House publicly downplayed — and contemporaneous reporting that Makary was preparing to step down. Makary was confirmed as FDA commissioner in March 2025. The New York Times said the agency’s top food official will serve as acting commissioner. Observers describe Makary’s tenure as tumultuous, marked by leadership upheaval, mass layoffs, political pressure and public disputes with drugmakers. Agency officials are scrambling to steady regulatory priorities, reassure stakeholders and manage an exit that leaves unfinished reviews and awkward staff memos.


Warning: Undefined variable $thumbnail in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 61


Related Stories



Warning: Undefined variable $top_stories in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 128

FDA Abortion Pill Decisions Rooted in Science / 4 months

FDA loosens data restrictions to accelerate drug reviews / 5 months

FDA Appoints Richard Pazdur to Lead Drug Division Amid Regulatory Shifts / 6 months

FDA links eight deaths to Amgen’s Tavneos; scrutiny intensifies / 1 month

FDA approves leucovorin for rare folate disorder despite autism hype / 2 months

FDA launches individualized therapy framework for ultra-rare diseases / 3 months

FDA makes one pivotal trial the default for drug approvals / 3 months

StackHealth RSS


You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Oncology, Drug Pricing, Pfizer, Pharmaceuticals and look for the RSS link.



NorthFeed Inc. Terms and Conditions / Privacy Policy

Disclaimer: The information provided on this website is intended for general informational purposes only. While we strive for accuracy, we do not guarantee the completeness or reliability of the content. Users are encouraged to verify all details independently. We accept no liability for errors, omissions, or any decisions made based on this information.